Company Performance Metrics
- Dmitry Ufaev: Co-Founder, CBDOPast Role: Lucky Ventures, Owner
Xelari is building the world’s first full-stack agentic AI platform for DNA/RNA molecular binder design.
Today, generating antibodies or aptamers takes months, costs $100K+, and often fails. Xelari replaces this with a simple web platform and API that delivers custom DNA/RNA binders — called XELAMERs — in just 24 hours.
Behind the
scenes, our proprietary agentic AI orchestrates 14 computational engines, predicting structure, affinity, specificity, and stability while optimizing binders for real-world use cases. Results are validated in partner labs, bridging computational speed with experimental reliability.
XELAMERs outperform traditional antibodies and aptamers with rapid design, controllable affinity, high specificity, stability, and lower cost. They enable pharma, biotech, diagnostics, CROs, and QC labs to accelerate discovery, reduce risk, and save hundreds of thousands per project.
Our go-to-market focuses on six verticals: aptamer CROs, multi-omics, AI drug discovery, biopharma, CDMO/QC suppliers, and diagnostics. With a TAM of $140B, we aim to make molecular binders as easy to order as software, unlocking a new infrastructure layer for the entire life sciences industry.
Xelari is a member of the NVIDIA Inception program, leveraging AI infrastructure to scale globally across the US, EU, and Asia.
